China Technology Fuels Biomedicine Expansion: Shanghai Henlius and XtalPi Lead the Charge

As China technology plays a pivotal role in the biomedicine sector, two major companies, Shanghai Henlius Biotech and XtalPi, have announced significant partnerships aimed at expanding their market presence internationally. These collaborations were unveiled at the China International Import Expo in Shanghai, showcasing the emerging trend of Chinese pharmaceutical firms seeking growth abroad.

Shanghai Henlius Expands into the Middle East

Fosun Group’s Shanghai Henlius has established a partnership with the Fakeeh family’s Al Tiryaq Al-Khalawi Medical Company (SVAX) in Saudi Arabia. This alliance is intended to bolster pharmaceutical production and marketing, integrating Henlius' advanced drug technologies with SVAX's local market knowledge. CEO Zhu Jun stated, “The collaboration is a key part of Henlius’ globalization blueprint…” The partnership will facilitate the introduction of two essential drugs for the Menat region: HLX03 Adalimumab for rheumatoid arthritis and HLX04 Bevacizumab for oncology treatments.

XtalPi's AI-Driven Innovations in Indonesia

Meanwhile, XtalPi, previously known for its revolutionary approaches to drug discovery through AI and quantum physics, has teamed up with Sinar Mas Multiartha in Indonesia. This venture aims to integrate AI and robotics in the drug development process, benefiting from Sinar Mas’ extensive supply chain and market reach in Asia-Pacific. Chairman Wen Shuhao noted this collaboration intends to create a sustainable health ecosystem for Southeast Asian consumers.

• Henlius will develop several drugs focused on various cancers.
• XtalPi aims to reshape drug discovery efficiency through AI.
• Both companies exemplify China's strategy to leverage technology for international market penetration.